Survival following primary androgen deprivation therapy among men with localized prostate cancer
about
Metabolic complications of androgen deprivation therapy for prostate cancerIntegrating diet and exercise into care of prostate cancer patients on androgen deprivation therapyEvaluating comparative effectiveness with observational data: endoscopic ultrasound and survival in pancreatic cancerFactors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1)Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cellsComparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data.Use of instrumental variable in prescription drug research with observational data: a systematic review.Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.Gene expression pathways of high grade localized prostate cancer.Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancerDuration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancerLifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an updatePrimary radiotherapy vs conservative management for localized prostate cancer--a population-based study.Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.Apples and oranges? Interpretations of risk adjustment and instrumental variable estimates of intended treatment effects using observational data.Contemporary role of androgen deprivation therapy for prostate cancerComparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art.Update on the management of prostate cancer with goserelin acetate: patient perspectivesUtilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy.Primary androgen deprivation therapy for prostate cancer in koreans: a retrospective multicenter study.Should cause of death from the death certificate be used to examine cancer-specific survival? A study of patients with distant stage disease.Clinical utility of denosumab for treatment of bone loss in men and womenEffectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer.Improved outcomes associated with higher surgery rates for older patients with early stage nonsmall cell lung cancer.An update on the changing indications for androgen deprivation therapy for prostate cancer.Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapyOsteoporosis in men: a review.Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancerReducing bias in the assessment of treatment effectiveness: androgen deprivation therapy for prostate cancer.Clinical outcomes of helical tomotherapy for super-elderly patients with localized and locally advanced prostate cancer: comparison with patients under 80 years of ageDoes primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?Methods in comparative effectiveness research.Role of hormonal therapy for prostate cancer: perspective from Japanese experiences.An economic analysis of conservative management versus active treatment for men with localized prostate cancerImproving the communication of benefits and harms of treatment strategies: decision AIDS for localized prostate cancer treatment decisions
P2860
Q24616159-4B18BAFA-161D-4E09-A5D6-8723046217A7Q26738281-B039A154-A3DD-4AED-8402-E0F3E19C746DQ30660055-FC9A8830-6508-427C-889B-EAE188B11168Q33559123-ED708711-D893-4888-B8BF-6C0404B96218Q33694557-4316C9E9-3A80-4F70-B357-267B67D8628EQ33718192-71C3AA57-3563-4EA8-905B-FD83FA623043Q33773119-A5C98985-FAD5-4906-BB11-AE44F421FFDDQ33789201-5E8C4852-883F-4FE5-AB48-84F642A95109Q33832517-D54C8F00-A25A-4888-BAF8-2B8E696B3D47Q33877542-0DD3FC2E-C1B9-489C-9A49-44A258FFEB74Q33899266-45A03D2A-10E8-469A-A05A-4F5C980FFD20Q33900049-B6ADABD7-4CF1-4AD4-87DB-3B5BD6DE1406Q33919551-2AEE794D-113F-492C-B1F6-4218F09C57A8Q33926384-EF2DC282-7C97-4870-B991-548E49C86E28Q33977523-752DACD3-E4E3-4AC5-BF6A-05D523A8BD13Q34013761-75815D84-7F1B-449C-B820-E46B46AA4000Q34074907-6ADC963A-8A29-4C4F-8B04-D90646100559Q34211155-45FA4DF9-F146-4DFB-BB51-25E6352BA9AEQ34288796-FB1E30E5-5086-410A-8D20-9C5E3171F192Q34296696-BFFC4DAA-E2AE-4C57-AD45-C3B29FA06A53Q34310143-B8C007B5-FD5C-4288-A87F-EBF4CFDA3221Q34417815-2B455CA5-6646-4699-A253-F71E80C390C3Q34418403-05074817-C592-424E-BA9B-51E9C5823AB2Q34823216-C500C7A9-0028-4896-99A5-F9E111C715CCQ34984105-176FC0BE-D8A7-41CB-9105-6BC0FEEF631EQ34990687-552C6B97-4320-42B2-9EE8-26597AC8CC0FQ35092799-B36FFAB9-58E3-4D17-9CB9-593242ED755CQ35102488-763B9DB5-2200-436C-83A9-0BB1D31C8C54Q35523070-12AC9316-D5DE-4557-84BF-5AAEC615AF4FQ35549863-2B7DBDA4-FCA5-437A-A621-A5FF9D1DD9B4Q35635497-9E2EAE57-4D6A-4073-B24C-34D617AD6E06Q35755160-185D5455-5187-497B-ABBD-85A3CA5FEF87Q35977154-21E30828-5793-4E20-9879-86F5796AE2ACQ35992569-089C9A8B-866C-43D2-91DC-ED51534505A9Q36234731-1BFBA84C-5B2B-4025-8BF0-83E72F991577Q36319986-BAC2DF03-610E-48D5-9431-80BCC8C2769AQ36417734-BE1FD94C-AA25-4FB2-9515-DA96097653A4Q36450795-F29CF79B-3087-4D7E-ACB0-464B789D72AAQ36520468-28EB3E83-0A4F-4B45-9E8F-D63D1F4B3FE4Q36520523-68D34D92-B40E-4F7B-8201-62F8946450B6
P2860
Survival following primary androgen deprivation therapy among men with localized prostate cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Survival following primary and ...... with localized prostate cancer
@en
type
label
Survival following primary and ...... with localized prostate cancer
@en
prefLabel
Survival following primary and ...... with localized prostate cancer
@en
P2093
P2860
P356
P1476
Survival following primary and ...... with localized prostate cancer
@en
P2093
Dirk F Moore
Grace L Lu-Yao
Peter C Albertsen
Robert S DiPaola
Siu-Long Yao
Weichung Shih
P2860
P304
P356
10.1001/JAMA.300.2.173
P407
P577
2008-07-01T00:00:00Z